LKB1-Dependent Regulation of TPI1 Creates a Divergent Metabolic Liability between Human and Mouse Lung Adenocarcinoma
Year: 2023
Type: article
Abstract: KRAS is the most frequently mutated oncogene in human lung adenocarcinomas (hLUAD), and activating mutations frequently co-occur with loss-of-function mutations in TP53 or STK11/LKB1. However, mutation of all three genes is rarely observed in hLUAD, even though engineered comutation is highly aggressive in mouse lung adenocarcinoma (mLUAD). Here, we provide a mechanistic explanation for this difference by uncovering an evolutionary divergence in the regulation of triosephosphate isomerase (TPI1). In hLUAD, TPI1 activity is regulated via phosphorylation at Ser21 by the salt inducible kinases (SIK) in an LKB1-dependent manner, modulating flux between the completion of glycolysis and production of glycerol lipids. In mice, Ser21 of TPI1 is a Cys residue that can be oxidized to alter TPI1 activity without a need for SIKs or LKB1. Our findings suggest this metabolic flexibility is critical in rapidly growing cells with KRAS and TP53 mutations, explaining why the loss of LKB1 creates a liability in these tumors. SIGNIFICANCE: Utilizing phosphoproteomics and metabolomics in genetically engineered human cell lines and genetically engineered mouse models (GEMM), we uncover an evolutionary divergence in metabolic regulation within a clinically relevant genotype of human LUAD with therapeutic implications. Our data provide a cautionary example of the limits of GEMMs as tools to study human diseases such as cancers. This article is highlighted in the In This Issue feature, p. 799.
Source: Cancer Discovery
Authors: Benjamin D. Stein, John R. Ferrarone, Eric E. Gardner, Jae Won Chang, David Wu, Pablo E. Hollstein, Roger J. Liang, Min Yuan, Qiuying Chen, John S. Coukos, Miriam Sindelar, Bryan Ngo, Steven S. Gross, Reuben J. Shaw, Chen Zhang, John M. Asara, Raymond E. Moellering, Harold Varmus, Lewis C. Cantley
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: hybrid
Funders: National Science Foundation, Alfred P. Sloan Foundation, Damon Runyon Cancer Research Foundation, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Division of Chemistry, Division of Diabetes, Endocrinology, and Metabolic Diseases
Awards: Metabolic remodeling of skeletal muscle in mitochondrial myopathies, Modulation of intermediate metabolism, a new therapeutic approach for mitochondrial encephalomyopathies, Medical Scientist National Research Service Award, Mechanisms and Models of Chromosomal Instability in Cancer, LKB1- AMPK pathway regulation of glucose metabolism and metformin action in liver, Pho-m6A assay: A phosphoselective method to quantify dynamics of m6A in mRNA, G5072372364, G5845404659, CAREER: Reactivity-Driven Metabolic Signaling: A Feature not a Flaw in Metabolic Regulation, G5986892838, G6671297155, G6987519018, G7227548224, G7592572939, G8379701072, G8744109046, Role of Phosphoinositides and Protein Kinases in the control of Cancer Metabolism, Molecular Pathogenesis of the Hamartoma Syndromes, Cancer Center Support Grant (CCSG), Medical Scientist National Research Service Award, Decoding And Targeting The LKB1-AMPK Signaling Pathway In Cancer
OpenAlex ID: W4318482016
